Human papillomavirus protein (HPV protein) (HPV protein)

Human papillomavirus (HPV) proteins are the essential components of the HPV virus, a small double-stranded DNA virus that infects epithelial cells (StatPearls, 2023). The viral proteome is divided into early proteins (E1, E2, E4, E5, E6, and E7) and late proteins (L1 and L2). The E6 and E7 proteins are characterized as potent oncoproteins; E6 facilitates the degradation of the p53 tumor suppressor, while E7 inactivates the retinoblastoma protein (pRb), collectively driving oncogenesis and cell cycle deregulation (PubMed, PMID: 29073643). The L1 and L2 proteins form the icosahedral capsid, with L1 being the primary target for prophylactic vaccines like Gardasil 9 and Cervarix, which induce neutralizing antibodies to prevent infection (NIH, National Cancer Institute). Therapeutic targeting of E6 and E7 is a major focus for treating established HPV-induced malignancies, utilizing DNA vaccines, RNA interference, and small molecule inhibitors to restore cellular growth control (Journal of Virology, 2021).

Other names

HPV viral proteinsHPV early proteinsHPV late proteinsHPV oncoproteinsHuman papillomavirus E6/E7 proteinsHuman papillomavirus L1/L2 proteinsHPV proteome

Prophylactic vaccines utilize recombinant L1 proteins to form virus-like particles (VLPs) that elicit a neutralizing antibody response, preventing viral attachment and entry into host cells (CDC, 2021). Therapeutic agents target the E6 and E7 oncoproteins to disrupt their interaction with p53 and pRb, respectively, thereby inducing apoptosis and senescence in malignant cells (Nature Reviews Cancer, 2019). Topical treatments like imiquimod act as toll-like receptor 7 (TLR7) agonists to stimulate a local immune response against HPV-infected cells (PubChem, CID 3689).